Samsara BioCapital’s Spyre Therapeutics SYRE Stock Holding History

Samsara BioCapital’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-35,349	Closed	-$398K	–	45
2023 Q2	$398K	Hold	35,349	–	–	0.07%	40
2023 Q1	$256K	Hold	35,349	–	–	0.05%	48
2022 Q4	$398K	Hold	35,349	–	–	0.09%	45
2022 Q3	$465K	Hold	35,349	–	–	0.11%	48
2022 Q2	$446K	Hold	35,349	–	–	0.12%	50
2022 Q1	$2.03M	Hold	35,349	–	–	0.51%	38
2021 Q4	$4.2M	Hold	35,349	–	–	0.81%	25
2021 Q3	$7.03M	Hold	35,349	–	–	1.1%	22
2021 Q2	$6.15M	Hold	35,349	–	–	0.76%	25
2021 Q1	$7M	Hold	35,349	–	–	1.29%	20
2020 Q4	$6.96K	Hold	35,349	–	–	0.7%	16
2020 Q3	$6.27M	Sell	35,349 -3,351	-9%	-$620K	1.75%	14
2020 Q2	$8.95M	Buy	+38,700	New	+$7.37M	2.88%	11

Other funds holding SYRE

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Samsara BioCapital's SYRE Position: Q3 2023 in Review

Samsara BioCapital sold out of Spyre Therapeutics (SYRE) in Q3 2023, closing a stake of 35,349 shares — an estimated $398K sold.

Samsara BioCapital first reported a position in SYRE in Q2 2020 and held it in 13 quarters. The position peaked at $8.95M in Q2 2020. 29 funds tracked by Wall St. Rank hold SYRE as of Q3 2023.

Samsara BioCapital reported no remaining Spyre Therapeutics position as of Q3 2023 after selling out during the quarter.
Samsara BioCapital sold 35,349 Spyre Therapeutics shares in Q3 2023, an estimated $398K.
Samsara BioCapital first reported a position in Spyre Therapeutics in Q2 2020 and held it in 13 quarters.
Samsara BioCapital's Spyre Therapeutics position peaked at $8.95M in Q2 2020.
29 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2023.

Based on Samsara BioCapital's 13F filing for Q3 2023, filed 14 Nov 2023.